PT Kalbe Farma Tbk (Kalbe) a Between a collaboration with PT Amarox Global Pharma (Amarox) to market the new Covid-19 drug, Movfor (Molnupiravir).
The new antiviral drug is indicated to treat Covid-19 patients over the age of 18 with mild to moderate symptoms, which do not require the administration of oxygen.
It is also recommended for people who do not have the potential to show severe symptoms of Covid-19 based on the latest edition of Indonesia Covid-19 Management Guidelines.
Molnupiravir has received Emergency Use Authorization (EUA) from Indonesia’s National Food and Drug Administration (BPOM RI) and the United States Food and Drug Administration (FDA) to treat the Covid-19.
Movfor would be the first branded Molnupiravir variant to receive EUA from BPOM RI.
On February 15, Amarox officially launched the drug in Indonesia.
Amarox Chief Executive Sandeep Sur said: “Referring to the Phase III clinical trial result, molnupiravir is effective on the current SARS-CoV-2 variant and has the potential to restrict infection. of the Omicron SARS-CoV-2 variant, resulting in 100% viral clearance by RT PCR result on day five.
Sandeep Sur also said that Movfor has also been sold and used in India and some ASEAN countries for the treatment of Covid-19.
Kalbe Director Mulia Lie said: “Kalbe has worked with Amarox as a primary marketing and distribution partner for other Covid-19 antiviral drugs, including Covifor (Remdesivir) and Fluvir (Oseltamivir) before this ( Press release).
“The collaborative effort to commercialize Movfor (Molnufiravir) is a continuation of this commitment. Hopefully, these three antiviral drugs will contribute to the national availability of Covid-19 treatment drugs accessible to the general public.
With the support of 76 distribution agencies in 34 provinces, Kalbe plans to accelerate and improve access and availability of the drug to treat Covid-19 in Indonesia.